Abd-AL Razzaq Albadri, Y., Abbass, M., Mahmood, A. (2023). Evaluation of Synchronous Metastatic Colonic Cancer Management; Single Center Experience; Short Term Outcome. Alustath, 22(4), 432-439. doi: 10.52573/ipmj.2023.182288
Yesor Jamal Abd-AL Razzaq Albadri; Mohamed Saleem Abbass; Aqeel Shakir Mahmood. "Evaluation of Synchronous Metastatic Colonic Cancer Management; Single Center Experience; Short Term Outcome". Alustath, 22, 4, 2023, 432-439. doi: 10.52573/ipmj.2023.182288
Abd-AL Razzaq Albadri, Y., Abbass, M., Mahmood, A. (2023). 'Evaluation of Synchronous Metastatic Colonic Cancer Management; Single Center Experience; Short Term Outcome', Alustath, 22(4), pp. 432-439. doi: 10.52573/ipmj.2023.182288
Abd-AL Razzaq Albadri, Y., Abbass, M., Mahmood, A. Evaluation of Synchronous Metastatic Colonic Cancer Management; Single Center Experience; Short Term Outcome. Alustath, 2023; 22(4): 432-439. doi: 10.52573/ipmj.2023.182288

Evaluation of Synchronous Metastatic Colonic Cancer Management; Single Center Experience; Short Term Outcome

Iraqi Postgraduate Medical Journal
Volume 22, Issue 4, October 2023, Pages 432-439    PDF (205.54 K)
Document Type: Review Article
DOI: 10.52573/ipmj.2023.182288
Authors
Yesor Jamal Abd-AL Razzaq Albadri* 1; Mohamed Saleem Abbass2; Aqeel Shakir Mahmood3
1Medical Oncologist \ Oncology Teaching Hospital , Baghdad ,Iraq.
2Consultant physician and Hematologists Baghdad Teaching Hospital.
3Consultant Surgical Oncologist Baghdad Teaching Hospital College of Medicine – Baghdad
Abstract
BACKGROUND:
Colorectal cancer is the fourth most frequently diagnosed cancer after lung, breast and prostate cancer, and the second leading cause of cancer death after lung cancer globally. Sometimes, distant metastases can cause the initial clinical symptoms. Synchronous metastatic colon cancer define as initially presented metastatic disease.
OBJECTIVE:
To evaluate the clinical presentations of patients with synchronous metastatic colon cancer, the outcome of current chemotherapy protocols used and their toxicity in our center for those  patients , and to correlate the different clinical and pathological parameters in patients with this disease .  
PATIENTS AND METHODS:
This is a hospital based prospective study would hold in Oncology Teaching Hospital Medical City during the period from 1 July 2019 – 1 July 2020. 50 patients would be recruited, all have evaluated by histopathological and radiological parameters, all diagnosed as metastatic colon cancer who are treated with chemotherapy and biological agents. All involved cases would be re-assessed after                  at least 4 cycles of treatment by physical examination, Lab investigations and Survival curve then demonstrate to shows the relation between the outcome and prognostic factors.
RESULTS:
In this study a total of 50 patients were involved ; All of them were diagnosed and treated for synchronous metastatic colonic cancer. the median age of diagnosis was 55.30 years, males in this study were higher than females (56% versus 44%); of enrolled patients 74% were with negative family history.Our study shows that the left side of involvement was the predominant (54%), and         the highest proportion of patients in both groups were with single metastasatic site (52%); and              the liver was the most common single site of metastasis in (40.0%) of patients In both groups,                the most frequent clinical features were altering bowel habit and abdominal pain which reported in (60.0%) the highest proportion of patients in our study were treated with both chemotherapy and target therapy, (78.0%) all of them were receive XELOX {xeloda tablet and oxaliplatin} as chemotherapy and Avastin as target one ; in both groups the commonest grade of differentiation is the grade two (82%); while adenocarcinoma was the commonest histopathological type (92%).              The primary tumor was resected in (62%) of patients all due to intestinal obstruction. Reassessment of all patients in both groups was done by Lab investigation and radiological assessment, the median progression free survival was 24.7 months.
CONCLUSION:
In our study, the progression with statistical significance was seen among patients with right sided tumor, patients with multiple sites of metastases, those who treated by Chemotherapy only without target therapies, and in patients who had mucinous adenocarcinoma .
 
Keywords
colon tumor; synchronous metastasis
References
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
  2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
  3. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age- related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2014:1-6.
  4. Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573-80.
  5. Obrand DI, Gordon PH. Continued change in the distribution of colorectal carcinoma. Br J Surg 1998;85:246–48.
  6. Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202-207.
  7. Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766-70.
  8. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-21.
  9. Iraqi Cancer Board. Results of the Iraqi Cancer Registry 2004. Baghdad, Iraqi Cancer Registry Center, Ministry of Health, 2018.
  10. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331: 1669–74.
  11. Cusack JC, Giacco GG, Cleary K, et al. Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. J Am Coll Surg 1996;183:105– 12.
  12. Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end re-sults— Medicare data. J Clin Oncol 2011;29:4401–9.
  13. Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis 1984;4:170-79.
  14. Grothey A, Marshall JL. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
  15. Hyder O, Dodson RM, Mayo SC, et al. Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery 2013;154:256-65.
  16. Kim K, Kim YW, Shim H, Kim BR, Kwon HY. Differences in clinical features and oncologic outcomes between metastatic right and left colon cancer. JBUON. 2018;23:11–8.
  17. Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020;9:361–73.
  18. Maisano R, Azzarello D, Maisano M, Mafodda A, Bottari M, Egitto G, et al. Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer. J Chemother. 2012;24:212–16.
  19. Nikiteas NI, Weber M, Antoniou A, Dimitroulis D. Advances in Colorectal Cancer. Biomed Res Int. 2016;2016.
  20. Sibiani AR, Shaheen M, Fallatah HI, Akbar HO, Qari YA, Bazaraa S, et al. Colorectal Cancer in Saudi Arabia King Abdul Aziz University Hospital: A Five Year Experience. J Med Med Sci. 2011;2:1126–30.
 

 

Statistics
Article View: 66
PDF Download: 32


Journal Management System. Powered by ejournalplus.com